AbbVie Inc. $ABBV Shares Sold by Warm Springs Advisors Inc.

Warm Springs Advisors Inc. decreased its position in AbbVie Inc. (NYSE:ABBV) by 3.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 9,945 shares of the company’s stock after selling 398 shares during the period. AbbVie comprises approximately 1.6% of Warm Springs Advisors Inc.’s portfolio, making the stock its 21st biggest holding. Warm Springs Advisors Inc.’s holdings in AbbVie were worth $1,846,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in ABBV. Nuveen LLC purchased a new position in AbbVie during the 1st quarter valued at about $1,819,154,000. Assenagon Asset Management S.A. grew its position in shares of AbbVie by 550.9% in the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after purchasing an additional 3,666,521 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of AbbVie by 31.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company’s stock valued at $3,068,820,000 after acquiring an additional 3,519,187 shares during the last quarter. Kingstone Capital Partners Texas LLC purchased a new position in AbbVie during the second quarter worth approximately $581,817,000. Finally, Invesco Ltd. raised its position in shares of AbbVie by 17.5% in the 1st quarter. Invesco Ltd. now owns 8,367,049 shares of the company’s stock worth $1,753,064,000 after buying an additional 1,246,863 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Activity at AbbVie

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of AbbVie stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the transaction, the executive vice president directly owned 177,292 shares of the company’s stock, valued at $35,178,278.64. This trade represents a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.25% of the stock is currently owned by insiders.

AbbVie Stock Performance

Shares of ABBV opened at $219.13 on Friday. The stock has a market capitalization of $387.11 billion, a P/E ratio of 104.35, a P/E/G ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 12-month low of $163.81 and a 12-month high of $244.81. The firm’s 50 day moving average is $223.06 and its 200-day moving average is $201.96. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company’s revenue was up 9.1% compared to the same quarter last year. During the same period last year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is currently 524.24%.

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their price target on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday. UBS Group set a $251.00 target price on AbbVie in a research report on Friday, October 3rd. Wells Fargo & Company upped their price objective on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Morgan Stanley lifted their price target on shares of AbbVie from $250.00 to $255.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $238.05.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.